- About
- Home
- Introduction
- Statistics
- Programs
- Dignet
- Gene
- GenePair
- Help & Docs
- Documents
- Help
- FAQs
- Links
- Acknowledge
- Disclaimer
- Contact Us
Gene Information
Gene symbol: PCSK9
Gene name: proprotein convertase subtilisin/kexin type 9
HGNC ID: 20001
Synonyms: NARC-1, FH3
Related Genes
| # | Gene Symbol | Number of hits |
| 1 | APOB | 1 hits |
| 2 | COG2 | 1 hits |
| 3 | INS | 1 hits |
| 4 | LDLR | 1 hits |
| 5 | LPAL2 | 1 hits |
| 6 | STN | 1 hits |
Related Sentences
| # | PMID | Sentence |
| 1 | 21889145 | Pro-protein convertase subtilisin/kexin type 9 (PCSK9) is a post-transcriptional inhibitor of LDL-receptor. |
| 2 | 21889145 | In non-diabetic men, plasma PCSK9 levels were found to be inversely correlated with low-density lipoprotein (LDL) apolipoprotein B100 (apoB) fractional catabolic rate (FCR). |
| 3 | 21889145 | In the non-diabetic group, plasma PCSK9 was positively correlated with LDL-C (r=0.64, p=0.001), apoB (r=0.67, p<0.001), and inversely correlated with LDL-apoB FCR (r=-0.61, p=0.002). |
| 4 | 21889145 | In contrast, in type 2 diabetic patients, plasma PCSK9 was not associated with LDL-C, apoB and LDL-apoB FCR. |
| 5 | 20649626 | Fenofibrate concomitantly decreased serum PCSK9 and VLDL particle concentrations in statin-treated T2DM patients. |
| 6 | 20619837 | Here, we determined how standard dose of statin and combined therapy with fenofibrate modulate PCSK9. |
| 7 | 21122860 | PCSK9 mRNA expression may be upregulated by insulin in murine models. |
| 8 | 21122860 | Individual absolute and relative changes in LDL cholesterol, apolipoprotein B and triglycerides after 24h of insulin were unrelated to changes in PCSK9 (P > 0.15 for all). |
| 9 | 21149300 | Insofar as PCSK9 inhibition induces a decrease in plasma cholesterol levels, understanding the nature of the binding interaction between PCSK9 and the LDLR is of critical importance. |
| 10 | 21149300 | Using a direct binding interaction assay, we show that the PCSK9 CT domain bound to the LDLR in a calcium-dependent manner and that co-incubation with the prodomain and catalytic domain had no effect on this binding. |
| 11 | 21149300 | Thus, CT domain interaction with the LBD of the LDLR at endosomal pH constitutes a second step in the PCSK9-mediated LDLR binding that leads to receptor degradation. |
| 12 | 21596380 | Proprotein convertase subtilisin kexin type 9 (PCSK9) is a circulating protein that impairs LDL clearance by promoting the LDL receptor (LDLR) degradation. |